ImmunOs Therapeutics AG FinancingImmunOs Therapeutics AG raises US$11m in Series C financingSwiss cancer and auto-immunity specialist ImmunOs Therapeutics AG has closed a Series C financing round of US$11m led by existing investors Gimv, Pfizer Ventures, Mission BioCapital, BioMed Partners … more ➔
BIOCOM Interrelations GmbHContract biomanufacturingRichter-Helm Biologics triples production capacityAfter three and a half years of construction, the CDMO Richter Biologics has inaugurated its new multipurpose production facility that triples the CDMO’s capacity for the bacterial production of pDNA, … more ➔
Phoremost LtdProtein DegradersPhoremost reports Series B extensionBritish protein degrader specialist PhoreMost Ltd has extended its €33m Series B financing to $50M and plans to advance its oncology and inflammation degrader programmes. more ➔
FinancingFunding for green insecticidesAgri-biotech SOLASTA Bio Ltd. has raised US$14m in a Series A funding round led by Forbion. With the money, the UK company will advance its first-of-a kind peptide-based bioinsecticide. more ➔
AstraZenecaPhase IIIAZ’s lung cancer drug disappointsA Phase III trial evaluating AstraZeneca and Daiichi Sankyo’s potential “blockbuster” lung cancer drug Dato-DXd showed no significant improvement over standard chemotherapy. Investors reacted quickly: … more ➔
King's CollegeAllergyEpsilogen Ltd completes £12.5m Series B expansionA new £12.5m Series B expansion brings Elipsogen Ltd’s total Series B funds raised to £43.25 million. The IgE antibody specialist will use the roceeds to support the delivery of clinical Proof of Concept … more ➔
Hayo Therapeutics SAObesitySwiss RNA maker Haya in huge licence dealSwiss HAYA Therapeutics SA has inked a US$1bn biobuck deal with pharma giant Eli Lilly to discover new lncRNA targets in obesity and related metabolic conditions. more ➔
Innerstream - wikimedia.orgMultiple sclerosisRoche with good interim clinical resultsRoche’s fenebrutinib demonstrated near-complete suppression of disease activity and disability progression after one year in patients with relapsing multiple sclerosis more ➔
Individor plcPartnershipIndividor set to waive AEF0117 licence after Phase IIb failureFollowing the failure of Aelis Farma’s lead candidate AEF0117 in a Phase IIb study in patients with cannabis use disorder or cannabis-induced psychosis, Individor plc has stated that it will not exercise … more ➔
Nxtera Pharma LtdDealNxera Pharma Ltd collects clinical US$35m milestoneNxera Pharma Ltd has got a Phase II milestone from US licencor Neurocrine Biosciences for its first-in class oral schizophrenia candidate NBI-1117568. more ➔
ImmunOs Therapeutics AG 
BIOCOM Interrelations GmbH
Phoremost Ltd
AstraZeneca
King's College
Hayo Therapeutics SA
Innerstream - wikimedia.org
Individor plc
Nxtera Pharma Ltd